GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bonus BioGroup Ltd (XTAE:BONS) » Definitions » Debt-to-Equity

Bonus BioGroup (XTAE:BONS) Debt-to-Equity : 0.70 (As of Jun. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Bonus BioGroup Debt-to-Equity?

Bonus BioGroup's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was ₪1.58 Mil. Bonus BioGroup's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was ₪9.15 Mil. Bonus BioGroup's Total Stockholders Equity for the quarter that ended in Jun. 2024 was ₪15.40 Mil. Bonus BioGroup's debt to equity for the quarter that ended in Jun. 2024 was 0.70.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bonus BioGroup's Debt-to-Equity or its related term are showing as below:

XTAE:BONS' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.9   Med: 0.19   Max: 1.11
Current: 0.7

During the past 12 years, the highest Debt-to-Equity Ratio of Bonus BioGroup was 1.11. The lowest was -0.90. And the median was 0.19.

XTAE:BONS's Debt-to-Equity is ranked worse than
81.03% of 1044 companies
in the Biotechnology industry
Industry Median: 0.14 vs XTAE:BONS: 0.70

Bonus BioGroup Debt-to-Equity Historical Data

The historical data trend for Bonus BioGroup's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bonus BioGroup Debt-to-Equity Chart

Bonus BioGroup Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.43 0.17 0.15 0.21 0.38

Bonus BioGroup Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 0.31 0.38 0.50 0.70

Competitive Comparison of Bonus BioGroup's Debt-to-Equity

For the Biotechnology subindustry, Bonus BioGroup's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bonus BioGroup's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bonus BioGroup's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bonus BioGroup's Debt-to-Equity falls into.



Bonus BioGroup Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bonus BioGroup's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Bonus BioGroup's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bonus BioGroup  (XTAE:BONS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Bonus BioGroup Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Bonus BioGroup's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Bonus BioGroup Business Description

Traded in Other Exchanges
Address
Matam Advanced, Technology Park, P.O.B 15143, Haifa, ISR, 31905
Bonus BioGroup Ltd is a biotechnology company. It generates viable tissue-regenerating bone grafts. The company treats skeletal disorders such as bone- and cartilage-related arthritis and various types of bone and joint trauma. It is in the field of tissue engineering, human adipose tissue-derived cells and live bone transplantation.

Bonus BioGroup Headlines

No Headlines